Societal costs of multiple sclerosis in Ireland

Carney, Peter; O'Boyle, D.; Larkin, Aidan; McGuigan, Christopher; O’Rourke, Killian

doi:10.1080/13696998.2018.1427100

Cited by 21 publications

(40 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The health utility ranged from 0.31 to 0.78 for multiple sclerosis patients in six studies (34)(35)(36)(37)(38)(39). The upper and lower utility values were generated with the crosswalk France value set (35) and the crosswalk UK value set (39), respectively.…”

Section: Multiple Sclerosismentioning

confidence: 99%

See 1 more Smart Citation

Health-Related Quality of Life in Patients With Different Diseases Measured With the EQ-5D-5L: A Systematic Review

Zhou

Guan

Wang

et al. 2021

Front. Public Health

103

View full text Add to dashboard Cite

Background: The EQ-5D-5L is a generic preference-based questionnaire developed by the EuroQol Group to measure health-related quality of life (HRQoL) in 2005. Since its development, it has been increasingly applied in populations with various diseases and has been found to have good reliability and sensitivity. This study aimed to summarize the health utility elicited from EQ-5D-5L for patients with different diseases in cross-sectional studies worldwide.Methods: Web of Science, MEDLINE, EMBASE, and the Cochrane Library were searched from January 1, 2012, to October 31, 2019. Cross-sectional studies reporting utility values measured with the EQ-5D-5L in patients with any specific disease were eligible. The language was limited to English. Reference lists of the retrieved studies were manually searched to identify more studies that met the inclusion criteria. Methodological quality was assessed with the Agency for Health Research and Quality (AHRQ) checklist. In addition, meta-analyses were performed for utility values of any specific disease reported in three or more studies.Results: In total, 9,400 records were identified, and 98 studies met the inclusion criteria. In the included studies, 50 different diseases and 98,085 patients were analyzed. Thirty-five studies involving seven different diseases were included in meta-analyses. The health utility ranged from 0.31 to 0.99 for diabetes mellitus [meta-analysis random-effect model (REM): 0.83, (95% CI = 0.77–0.90); fixed-effect model (FEM): 0.93 (95% CI = 0.93–0.93)]; from 0.62 to 0.90 for neoplasms [REM: 0.75 (95% CI = 0.68–0.82); FEM: 0.80 (95% CI = 0.78–0.81)]; from 0.56 to 0.85 for cardiovascular disease [REM: 0.77 (95% CI = 0.75–0.79); FEM: 0.76 (95% CI = 0.75–0.76)]; from 0.31 to 0.78 for multiple sclerosis [REM: 0.56 (95% CI = 0.47–0.66); FEM: 0.67 (95% CI = 0.66–0.68)]; from 0.68 to 0.79 for chronic obstructive pulmonary disease [REM: 0.75 (95% CI = 0.71–0.80); FEM: 0.76 (95% CI = 0.75–0.77)] from 0.65 to 0.90 for HIV infection [REM: 0.84 (95% CI = 0.80–0.88); FEM: 0.81 (95% CI = 0.80–0.82)]; from 0.37 to 0.89 for chronic kidney disease [REM: 0.70 (95% CI = 0.48–0.92; FEM: 0.76 (95% CI = 0.74–0.78)].Conclusions: EQ-5D-5L is one of the most widely used preference-based measures of HRQoL in patients with different diseases worldwide. The variation of utility values for the same disease was influenced by the characteristics of patients, the living environment, and the EQ-5D-5L value set.Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/, identifier CRD42020158694.

show abstract

Section: Multiple Sclerosismentioning

confidence: 99%

“…In addition, the former had a higher proportion of relapsingremitting multiple sclerosis patients than the latter (71.5 vs. 52.8%). EQ-5D VAS scores ranged from 58.3 to 78.0 in five studies (35)(36)(37)(38)(39). Pain/discomfort and usual activities were the dimensions with the most reported problems among multiple sclerosis patients.…”

Section: Multiple Sclerosismentioning

confidence: 99%

Health-Related Quality of Life in Patients With Different Diseases Measured With the EQ-5D-5L: A Systematic Review

Zhou

Guan

Wang

et al. 2021

Front. Public Health

103

View full text Add to dashboard Cite

show abstract

“…2829 A population based cohort study found that people with MS have a threefold higher risk of hip fracture than age and gender matched peers with a greater risk for those prescribed steroids in the previous six months. 30 Injurious falls can result in increased healthcare utilisation and decreased labour force productivity which both contribute to the high socio-economic cost associated with MS 31,32 .…”

Section: Consequences Of Fallsmentioning

confidence: 99%

“…However, this protective response may result in some people with MS curtailing their activities inappropriately, resulting in further deconditioning and adversely affecting physical function and independence s. 40 This adverse response should be avoided especially due to the growing body of evidence highlighting the benefits of regular physical activity for MS. 41 Most concerning is that studies have consistently found that fallers have lower quality of life than non-fallers 14,42 Lower quality of life, in turn, has higher associated socio-economic costs, and contributes significantly to the intangible costs and burden for the person with MS related to issues around self-care, pain, anxiety and depression. 32 Nilsagard et al 43 qualitatively explored the context and impact of accidental falls in pwMS, with participants describing falls as limiting, restrictive and embarrassing.…”

Section: O N L I N E F I R S Tmentioning

confidence: 99%

Falls in People with Multiple Sclerosis

Coote¹,

Comber²,

Quinn³

et al. 2020

International Journal of MS Care

View full text Add to dashboard Cite

Falls are highly prevalent for people with Multiple Sclerosis (MS) and result in a range of negative consequences such as injury, activity curtailment, reduced quality of life, increased need for care and time off work. This narrative review aims to summarise key literature and to discuss future work needed in the area of falls prevention for people with MS. The incidence of falls is estimated to be over 50%; similar to the rate of falls in adults over 80 years. The consequences of falls are considerable as rate of injury is high, and fear of falling and low self-efficacy are significant problems that lead to activity curtailment. A wide range of physiological, personal and environmental factors have been highlighted as potential risk factors and predictors of falls. Falls are individual and multifactorial, and hence approaches to interventions will likely need to adopt a multi-factorial approach. However, the literature to date has largely focused on exercise-based interventions, with newer more comprehensive interventions using both education and exercise showing promising results. Several gaps remain in the topic of falls in MS and in particular the lack of standardisation of definitions and outcome measures to enable data pooling and comparison. In future, the involvement of people with MS in the design and evaluation of programmes is essential, as are approaches to intervention development that consider implementation from the outset.

show abstract

“…The social costs of MS are higher than those associated with strokes or Alzheimer's disease. It is associated with onset in early to middle adulthood, duration of the disease (It has a relatively small impact on life expectancy, so there is a need to treat the patient for many years), early loss of work capacity due to disability, wide range of symptoms, the need for care and assistance in carrying out daily activities, and the high cost of immunomodulatory therapies or interdisciplinary medical care [4,5]. Due to the increase of disability and the impact of the disease on daily functioning, most patients need social support from their environment.…”

Section: Introductionmentioning

confidence: 99%

Clinical and Sociodemographic Variables and the Level of Social Support in People with Multiple Sclerosis

Dymecka

2019

PNIN

View full text Add to dashboard Cite

Introduction. Multiple sclerosis (MS) is a chronic progressive demyelinating disease of the central nervous system which leads to permanent disability. Social support is a resource that is particularly important in the situation of chronic illness. Aim. The aim of the study was to determine the relationship between clinical and sociodemographic variables and the level of social support in people with multiple sclerosis. Material and Methods. 137 people diagnosed with MS participated in the study. Extended Disability Status Scale (EDSS), Guy’s Neurological Disability Scale (GNDS) and Berlin Social Support Scales were used in the study. Results. Perceived social support is not related to clinical variables such as disability or disease symptoms. However, the relationship between the need for support and disability and some symptoms (i.a. cognitive impairment, mood disorders and intestinal problems) was demonstrated. Women, people married, having children and in better financial condition felt greater social support. Women also need more support and more often seek it. Conclusions. Perceived social support in people with multiple sclerosis is less associated with clinical variables, but more to variables such as gender, marital status or having children. Of the studied types of support, the need for support was most related to the features of the disease. People living with a disability or more severe symptoms need help in daily functioning as well as emotional support. This is also associated with the need for professional support from doctors, psychologists and nurses. (JNNN 2019;8(4):148–156) Key Words: Multiple sclerosis, social support, disability

show abstract

Societal costs of multiple sclerosis in Ireland

Cited by 21 publications

References 36 publications

Health-Related Quality of Life in Patients With Different Diseases Measured With the EQ-5D-5L: A Systematic Review

Health-Related Quality of Life in Patients With Different Diseases Measured With the EQ-5D-5L: A Systematic Review

Falls in People with Multiple Sclerosis

Clinical and Sociodemographic Variables and the Level of Social Support in People with Multiple Sclerosis

Contact Info

Product

Resources

About